iGlarLixi for type 2 diabetes: a systematic review and meta-analysis

To assess the efficacy and tolerability of iGlarLixi—a novel, fixed-ratio, soluble combination of insulin glargine and lixisenatide—for the treatment of type 2 diabetes (T2D). The PubMed, Embase, Cochrane Library and ClinicalTrials.gov databases were searched from inception to November 15, 2023 to identify randomized controlled trials (RCTs) comparing iGlarLixi with a placebo or any other antidiabetic agent in adults with T2D. Risk ratios (RRs) and mean differences (MDs) with 95